MARKET

CRBU

CRBU

Caribou Biosciences, Inc.
NASDAQ
1.820
+0.110
+6.43%
Pre Market: 1.800 -0.02 -1.11% 08:46 03/09 EDT
OPEN
1.660
PREV CLOSE
1.710
HIGH
1.830
LOW
1.660
VOLUME
504
TURNOVER
0
52 WEEK HIGH
3.535
52 WEEK LOW
0.6600
MARKET CAP
175.88M
P/E (TTM)
-1.0721
1D
5D
1M
3M
1Y
5Y
1D
Caribou Biosciences price target raised to $13 from $11 at Evercore ISI
TipRanks · 33m ago
Analysts Are Bullish on Top Healthcare Stocks: Caribou Biosciences (CRBU), Oncology Institute (TOI)
TipRanks · 1h ago
Weekly Report: what happened at CRBU last week (0302-0306)?
Weekly Report · 2h ago
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Ardent Health Partners, Inc. (ARDT) and Caribou Biosciences (CRBU)
TipRanks · 4h ago
Caribou Biosciences: Advancing Allogeneic Cell Therapy Pipeline and Pivotal Trial Plans Support High-Risk Buy Rating
TipRanks · 1d ago
Drug Pricing Reforms Threaten Caribou Biosciences’ Future Margins and Market Access
TipRanks · 2d ago
Caribou Biosciences Q3 Losses Reinforce Bearish Narratives On Profitability Risks
Simply Wall St · 2d ago
Leerink Partners Remains a Buy on Caribou Biosciences (CRBU)
TipRanks · 2d ago
More
About CRBU
Caribou Biosciences, Inc. is a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company engaged in developing transformative therapies for patients with devastating diseases. The Company’s genome-editing platform, including its Cas12a chRDNA technology, enables superior precision to develop cell therapies that are armored to potentially improve activity against disease. Caribou is advancing a pipeline of off-the-shelf cell therapies from its CAR-T platform to offer broad access and rapid availability of treatments for patients with hematologic malignancies and autoimmune diseases. Its genome-editing platform, including its novel chRDNA technology, enables more precise genome editing of allogeneic cell therapies. It is advancing its pipeline of allogeneic CAR-T cell therapies with clinical development programs targeting the treatment of hematologic malignancies and autoimmune diseases.

Webull offers Caribou Biosciences Inc stock information, including NASDAQ: CRBU real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CRBU stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CRBU stock methods without spending real money on the virtual paper trading platform.